A Multicenter, Randomized, Parallel-Group, Double-blind, Fixed-Dose, 28-Day Trial to Assess the Efficacy and Safety of SCH 900435 Compared With Placebo, Using Olanzapine as an Active Control in Subjects With an Acute Exacerbation of Schizophrenia (GUEST - Glycine Uptake Inhibitor Efficacy and Safety Trial, Phase 2, Protocol No. P06079).

Trial Profile

A Multicenter, Randomized, Parallel-Group, Double-blind, Fixed-Dose, 28-Day Trial to Assess the Efficacy and Safety of SCH 900435 Compared With Placebo, Using Olanzapine as an Active Control in Subjects With an Acute Exacerbation of Schizophrenia (GUEST - Glycine Uptake Inhibitor Efficacy and Safety Trial, Phase 2, Protocol No. P06079).

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2013

At a glance

  • Drugs ORG 25935 (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms GUEST
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 28 Sep 2010 Planned initiation date changed from 1 Jun 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 28 Sep 2010 Planned end date changed from 1 Nov 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top